Transcenta is a global biotherapeutics company that fully integrates antibody-based discovery, development and manufacturing. Its core programs include TST001, a CLDN18.2-targeting antibody advancing in clinic in both the US and China, and TST005, a second-generation PD-L1–TGFβ bifunctional molecule for which an IND filing is planned soon. The company operates a Discovery and Translational Research Center in Suzhou, a Process and Product Development Center and manufacturing facility in Hangzhou, clinical development centers in Princeton (US), Beijing, Shanghai and Guangzhou (China), and an External Partnering Center in Boston (US). Transcenta has expanded its Hangzhou facility with a fill & finish line and 2,000L bioreactors, and its perfusion biomanufacturing platform has achieved productivity of more than 4 g/L per day and successful scale-up to 200L for GMP production of an in-house bispecific. It has also signed strategic partnerships with international technology innovators such as Merck KG to advance continuous manufacturing capabilities. The company plans to use new funding to accelerate ongoing clinical programs and prepare for commercialization.

Total raised

$105M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2020